EP 1218008 A2 20020703 - NEW USE OF 1,2,4-TRIAZOLO¬1,5-A PYRIMIDINES
Title (en)
NEW USE OF 1,2,4-TRIAZOLO¬1,5-A PYRIMIDINES
Title (de)
NEUE VERWENDUNG VON 1,2,4-TRIAZOLO¬1,5-A PYRIMIDINEN
Title (fr)
NOUVELLE UTILISATION DE 1,2,4-TRIAZOLO¬1,5-A PYRIMIDINES
Publication
Application
Priority
- EP 0005543 W 20000616
- GB 9914743 A 19990624
Abstract (en)
[origin: WO0100186A2] A method of treating obesity and related conditions comprising the administration of a therapeutically effective amount of a compound of formula (I) including pharmaceutically acceptable salts, solvates, racemates, enantiomers, diastereoisomers and mixtures thereof in which: R1 represents H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6alkyl, C1-6alkoxy or C1-6alkanoyl; R2 and R3 independently represent H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6alkyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkylthio, C1-6alkylsulphinyl, C1-6alkylsulphonyl or hydroxy; R4 and R5 independently represent H, C1-6alkyl or R4 and R5 combined together with the carbon atom to which they are attached represent C3-6cycloalkylidene (each alkyl or cycloalkylidene being optionally substituted with one or more of halo, cyano, hydroxy, amino or C1-6alkyl); and R6, R7 and R8 independently represent H, halo, hydroxy, mercapto, nitro, cyano or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino; and any nitrogen atom being optionally substituted with one or more C1-6alkyl): C1-6alkyl, C1-6alkanoyl, C1-6alkoxy, C2-6alkoxycarbonyl, carboxy, C1-6alkanoyloxy, C1-6alkylthio, C1-6alkylsulphinyl, C1-6alkylsulphonyl, C1-6alkylsulphonylamino, sulphamoyl, carbamoyl, C2-6alkylcarbamoyl or C1-6alkanoylamino; to a mammal in need thereof.
[origin: WO0100186A2] A method of treating obesity and related conditions, selected from eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, comprising the administration of therapeutically effective amount of a compound of formula I including pharmaceutically acceptable salts, solvates, racemates, enatiomers, diastereoisomers and mixtures thereof. Most preferred compounds are 7-[1-(4-halophenoxy) ethyl] 1,2,4,-triazolo [1,5a] pyrimidines
IPC 1-7
A61K 31/519; A61P 3/00; A61P 3/04; A61P 3/06; A61P 3/08; A61P 25/34; A61P 25/20
IPC 8 full level
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61P 25/00 (2006.01); A61P 25/20 (2006.01); A61P 25/34 (2006.01)
CPC (source: EP)
A61K 31/519 (2013.01); A61P 3/00 (2017.12); A61P 3/04 (2017.12); A61P 3/06 (2017.12); A61P 3/08 (2017.12); A61P 3/10 (2017.12); A61P 25/00 (2017.12); A61P 25/20 (2017.12); A61P 25/34 (2017.12)
Citation (search report)
See references of WO 0100186A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0100186 A2 20010104; WO 0100186 A3 20020510; AU 6150200 A 20010131; CA 2376886 A1 20010104; EP 1218008 A2 20020703; GB 9914743 D0 19990825; JP 2003503343 A 20030128; MX PA01013421 A 20020730
DOCDB simple family (application)
EP 0005543 W 20000616; AU 6150200 A 20000616; CA 2376886 A 20000616; EP 00947848 A 20000616; GB 9914743 A 19990624; JP 2001505896 A 20000616; MX PA01013421 A 20000616